Roche seeking earlier use for Lunsumio in FL on Phase III data
Lunsumio has accelerated approval for third-line use, but Roche hopes the study will secure its use in the second line.
Therapy Area
Podcast: What’s new in pulmonary fibrosis: Insights from ERS 2026
Axoltis’ Phase II ALS trial fails; company points to exploratory endpoints
J&J’s Rybrevant linked to longest median OS in exon 20 EGFR NSCLC
AbbVie eyes extended Qulipta use case on Phase III menstrual migraine win
Biohaven’s epilepsy drug hit with FDA clinical hold
Akeso and Summit’s ivonescimab meets OS goals in NSCLC
Can CNS trial momentum convert into late-stage evidence?
